Evaluating of Two Type of Cyclosporine-A Containing Nanosuspension for Ophthalmic Administration

Dry eye is both a common symptom and disease. It known that the ophthalmic emulsion of immunomodulator cyclosporine-A (Cyc-A) has positive effect on this condition but its’ absorption to intraocular tissues limited. Nanosuspension drug formulation aims increase bioavailability. The aim study was develop Cyc-A nanosuspension for better via ocular delivery investigate effectiveness by comparing it with two marketed emulsions (Restasis® Depores®). Two type loaded Eudragit S100 (A B) were prepared. Drug formulations applied eyes 20 male Albino New Zealand rabbits an interval 12 hours 14 days. In vitro release tested using dialysis sac quantitative analysis performed HPLC evaluating amounts in all formulations. Although four had similar particle size polydispersity indexes, B which zeta potential value, released more than other showed good tolerability could be alternative commercial treatment dry eye. nanosuspensions have ideal mean range surface charge applications Cyc-A.